Can Immunity to Breast Cancer Eliminate Residual Micrometastases?

An effective immune response has the potential for breast cancer sterilization with marked reduction in the potential for disease relapse. Adaptive type I immune cells uniquely have the capability of (i) cytotoxic T-cell activation and proliferation until all antigen expressing cells are eradicated, (ii) traversing endothelial barriers to penetrate tumor deposits wherever they occur, and (iii) immunologic memory, which allows the persistence of destructive immunity over the years it may take for breast cancer micrometastases to become clinically evident. Numerous recent investigations suggest that some breast cancers stimulate the type of immunity that results in a decreased risk of relapse. Moreover, the endogenous type I tumor microenvironment or type I immunity induced by drugs or biologic agents may improve response to standard therapies, further lowering the probability of disease recurrence. Clin Cancer Res; 19(23); 6398–403. ©2013 AACR.

[1]  M. Ellis,et al.  Incorporating Genomics into Breast Cancer Clinical Trials and Care , 2013, Clinical Cancer Research.

[2]  J. Baselga,et al.  Neoadjuvant Therapy as a Platform for Drug Development and Approval in Breast Cancer , 2013, Clinical Cancer Research.

[3]  Hailing Lu,et al.  The Invisible Arm of Immunity in Common Cancer Chemoprevention Agents , 2013, Cancer Prevention Research.

[4]  J. Bergh,et al.  Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis , 2013, Genome Biology.

[5]  K. Schäkel,et al.  Impact of chemotherapeutic agents on the immunostimulatory properties of human 6‐sulfo LacNAc+ (slan) dendritic cells , 2013, International journal of cancer.

[6]  E. Jaffee,et al.  Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective. , 2012, Cancer research.

[7]  A. Stojadinovic,et al.  Clinical trial results of the HER‐2/neu (E75) vaccine to prevent breast cancer recurrence in high‐risk patients , 2012, Cancer.

[8]  D. Matei,et al.  Abstract 3439: Tissue tranglutaminase (TG2) targeting by multifunctional field responsive gold nanoparticles , 2012 .

[9]  C. Sautès-Fridman,et al.  The immune contexture in human tumours: impact on clinical outcome , 2012, Nature Reviews Cancer.

[10]  L. Zitvogel,et al.  The secret ally: immunostimulation by anticancer drugs , 2012, Nature Reviews Drug Discovery.

[11]  David Haussler,et al.  Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling , 2011, Proceedings of the National Academy of Sciences.

[12]  P. Fumoleau,et al.  T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival , 2011, British Journal of Cancer.

[13]  D. Yin,et al.  CD8+ cytotoxic T cell and FOXP3+ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes , 2011, Breast Cancer Research and Treatment.

[14]  Xiaoling Hu,et al.  TNFα Cooperates with IFN-γ to Repress Bcl-xL Expression to Sensitize Metastatic Colon Carcinoma Cells to TRAIL-mediated Apoptosis , 2011, PLoS ONE.

[15]  Lajos Pusztai,et al.  A clinically relevant gene signature in triple negative and basal-like breast cancer , 2010, Breast Cancer Research.

[16]  P. Gattuso,et al.  Major histocompatibility complex class I-related chain A/B (MICA/B) expression in tumor tissue and serum of pancreatic cancer: Role of uric acid accumulation in gemcitabine-induced MICA/B expression , 2011, BMC Cancer.

[17]  M. Disis Immune regulation of cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Soldano Ferrone,et al.  Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  M. Greene,et al.  The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. , 2010, Cancer cell.

[20]  Johan Staaf,et al.  Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  S. Altiok,et al.  Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. , 2010, The Journal of clinical investigation.

[22]  Carsten Denkert,et al.  Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  J. Waisman,et al.  Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  R. Coombes,et al.  The effects of trastuzumab on the CD4+CD25+FoxP3+ and CD4+IL17A+ T-cell axis in patients with breast cancer , 2009, British Journal of Cancer.

[25]  Ping Zhang,et al.  Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis. , 2008, Molecular immunology.

[26]  J. Waisman,et al.  Level of HER-2/neu protein expression in breast cancer may affect the development of endogenous HER-2/neu-specific immunity , 2008, Molecular Cancer Therapeutics.

[27]  D. Petrylak,et al.  Augmented HER-2–Specific Immunity during Treatment with Trastuzumab and Chemotherapy , 2007, Clinical Cancer Research.

[28]  H. Nisenbaum,et al.  Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. , 2007, Cancer research.

[29]  F. Penault-Llorca,et al.  Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? , 2006, British Journal of Cancer.